An effective respiratory syncytial virus vaccination is now available for use after years of unsuccessful research. Shots created by Pfizer and GSK are presently undergoing regulatory assessment in the U.S. If the shots are approved by the FDA, they will represent a long-awaited advancement in the fight against a common and fatal illness.
The New England Journal of Medicine released the complete findings of two significant clinical trials conducted by Pfizer, providing the medical world with a more thorough examination of the evidence in favor of that company’s vaccine for use in pregnant women and older persons. Several medical professionals believe that the Pfizer data will support the prevention of RSV infection in the young and old.
Approval of RSV vaccine for pregnant women and the elderly
- Pfizer’s RSV vaccine is undergoing regulatory assessment in the US
- Anticipation for FDA’s decision to approve the vaccine for pregnant women and older persons
- RSV is harmful to young children and the elderly, with the elderly at higher risk for hospitalization due to the RSV vaccine
- Children under six months are at higher risk of health problems and mortality
Effectiveness of Pfizer’s RSV vaccine
- Pfizer’s RSV vaccine is an injection that protects against both strains of the virus (A & B)
- The RENOIR research included over 36,000 persons aged 60 years or older
- The vaccine was 67% effective at protecting against two symptoms
- The vaccine had an 86% success rate against more serious illnesses
The findings demonstrate that protection was uniform across subgroups and lasted during the first RSV season. Also, researchers found that Pfizer’s vaccine was 62% effective in preventing acute respiratory illnesses brought on by RSV infection.
The results from the maternal research were very different. It included 7,400 pregnant women who received a vaccination before giving birth. Between 90 and 180 days after birth, vaccination protected babies from severe RSV-related lower respiratory tract disease that required medical attention.
According to several researchers, the experiment did not include pregnant women with high-risk pregnancies since those babies could have a higher chance of developing serious illnesses.
Sanofi and AstraZeneca have jointly developed this monoclonal antibody, which has been demonstrated to be effective in preventing lower respiratory tract infections that require medical attention associated with RSV for up to 150 days. This antibody may soon be accessible to safeguard newborns, as it is being assessed in the US after just seeking approval in Europe.
Researchers raised no significant concerns about the safety of Pfizer’s vaccine in the trial. Adverse event rates were minimal in RENOIR, despite being marginally higher among individuals who got the vaccination. Participants in the maternal trial who received the vaccination had greater rates of headache and muscular discomfort, as well as local side effects like redness and soreness at the injection site.
A company representative stated:
“These efforts have been made with care to avoid the tragic enhanced RSV illness that occurred in the 1960s in children who had not previously been infected with RSV and who received a formalin-inactivated RSV vaccine.”